EUVIMEDOpdag EUVIMED
Open access

Practical Recommendations for Implementing Remote Patient Monitoring for Patients Receiving Bispecific Antibodies for Multiple Myeloma

Cindy Varga, Eric Schaefer

JMIR Cancer · 2026-11-05 · 12 · e95949-e95949

DOI: 10.2196/95949 ↗

At a glance

Journal article in JMIR Cancer, published online on 2026-11-05. Written by Cindy Varga and 1 co-authors. Institution: Department of Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer Institute, 1021 Morehead Medical Drive, Charlotte, NC, 28204, Uni…. Major MEDLINE topics: Antibodies, Bispecific, Multiple Myeloma. 49 references. The full text is freely available in PubMed Central.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Bispecific antibodies are novel immunotherapies approved for the treatment of patients with relapsed or refractory multiple myeloma (MM). While these therapies induce deep and durable responses, they are associated with adverse events, such as cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome, that require specific protocols for monitoring, prevention, and treatment. Due to the potential risk of cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome, current US labeling recommends inpatient administration during step-up dosing of bispecific antibodies, which typically occurs in academic centers and can often restrict the number of patients that can be treated. The administration of bispecific antibodies in the outpatient and community setting can enhance the patient experience and reduce resource use, which is a barrier to the widespread uptake of these treatments. With bispecific antibodies being evaluated in earlier lines of therapy for MM, the broader use of these agents will underscore the need for more accessible and less resource-intensive options that ensure safe outpatient administration. In this Viewpoint, we aim to provide practical recommendations built from our own real-world perspectives and case examples for institutions seeking to implement remote patient monitoring (RPM) strategies to support the outpatient dosing of bispecific antibodies in patients with MM. We discuss how the use of RPM has the potential to improve adverse event detection and management, improve patient outcomes, and decrease resource use and costs. While specific approaches will vary based on the needs of each treatment center, our experiences suggest that RPM implementation can be safe and feasible for both academic and community practices.

Subjects

MeSH terms (MEDLINE)

Antibodies, BispecificMultiple MyelomaHumansImmunotherapyRemote Patient Monitoring

Author keywords

bispecific antibodiesimmunotherapymultiple myelomaoutpatient monitoringremote patient monitoring

Substances

Antibodies, Bispecific

Authors and institutions

  • Department of Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer Institute, 1021 Morehead Medical Drive, Charlotte, NC, 28204, United States, 1 980-442-4363.
  • Department of Medical Oncology, Highlands Oncology Group, Fayetteville, AR, United States.

Cite

APA

Varga, C., & Schaefer, E. (2026). Practical Recommendations for Implementing Remote Patient Monitoring for Patients Receiving Bispecific Antibodies for Multiple Myeloma. JMIR Cancer, 12, e95949-e95949. https://doi.org/10.2196/95949

Vancouver

Varga C, Schaefer E. Practical Recommendations for Implementing Remote Patient Monitoring for Patients Receiving Bispecific Antibodies for Multiple Myeloma. JMIR Cancer. 2026;12:e95949-e95949. doi:10.2196/95949

BibTeX
@article{Varga2026,
  author = {Varga, Cindy and Schaefer, Eric},
  title = {Practical Recommendations for Implementing Remote Patient Monitoring for Patients Receiving Bispecific Antibodies for Multiple Myeloma},
  journal = {JMIR Cancer},
  year = {2026},
  volume = {12},
  pages = {e95949--e95949},
  doi = {10.2196/95949}
}
Start for free →